TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 14716420
Drug: Hapavax-Gene vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hapavax-Gene vaccine (10 microgram doses for ages 10-19, 20 microgram doses for ages over 19) administered intramuscularly in three doses: day 0, after 30 days, and after 180 days.
Study: 7917735
Drug: suxamethonium 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: suxamethonium 1.5 mg kg‐1
Study: 20112574
Drug: Infrared therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infrared therapy
Study: 15306594
Drug: PhiCal test
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: PhiCal test (calprotectin level > or =50 microg/g)
Study: 8292066
Drug: Compressed naproxen
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Compressed naproxen suppositories (250 mg)
Study: 8292066
Drug: Standard naproxen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard naproxen tablet
Study: 30955977
Drug: Chemotherapy (investigator's
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (investigator's choice of platinum-based chemotherapy for four to six cycles)
Study: 26924360
Drug: O-(beta-Hydroxyethyl)-rutosides (Oxerutin),
Approvals — FDA: no, EMA: no, PMDA: no
Description: O-(beta-Hydroxyethyl)-rutosides (Oxerutin), 500 mg po q12hr
Study: 22035463
Drug: Aliskiren 150
Normalized name: aliskiren 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aliskiren 150 mg once daily
Study: 19145003
Drug: Aliskiren 300
Normalized name: aliskiren 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aliskiren 300 mg once daily
Study: 22035463
Drug: Aliskiren 300
Normalized name: aliskiren 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aliskiren 300 mg once daily + HCTZ 12.5 mg once daily
Study: 22035463
Drug: Aliskiren 300
Normalized name: aliskiren 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aliskiren 300 mg once daily + HCTZ 25 mg once daily
Study: 14651394
Drug: Digital rectal
Normalized name: BD Thermometer Digital Rectal (obsolete)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digital rectal examination or PSA test
Study: 11089748
Drug: 0.2% chlorhexidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% chlorhexidine gel, three times a day during the ICU stay
Study: 17279004
Drug: Standard oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard oral care
Study: 10334346
Drug: Prednisolone acetate
Normalized name: Prednisolone Acetate
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone acetate 1.0% ophthalmic suspension
Study: 8452179
Drug: Fleroxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fleroxacin (400 mg) given as a single dose
Study: 8452179
Drug: Fleroxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fleroxacin (400 mg) given once daily for 3 days
Study: 3940260
Drug: Loperamide (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loperamide (12 mg)
Study: 27082519
Drug: Nasal oxygen
Normalized name: TUBE,NASAL OXYGEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal oxygen insufflation (100 mL/kg/min, estimated 37% FiO2, n = 9)
Study: 20691328
Drug: New cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: New cognitive behavioural treatment
Study: 20691328
Drug: Behaviour therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behaviour therapy (leading alternative psychological treatment)
Study: 9475020
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no adjunctive antimetabolites)
Study: 7947383
Drug: Nisoldipine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nisoldipine (20 mg once daily)
Study: 2828249
Drug: Monotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy with theophylline
Study: 2828249
Drug: Monotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy with terbutaline
Study: 30509185
Drug: Specific micronutrient
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific micronutrient combination
Study: 21937705
Drug: Vinorelbine/Gemcitabine doublet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinorelbine/Gemcitabine doublet (VG arm: vinorelbine 25 mg/m2; gemcitabine 1000 mg/m2 on days 1 and 15)
Study: 21937705
Drug: Capecitabine (Cap
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capecitabine (Cap arm: 1250 mg/m2 twice daily, on days 1-14)
Study: 29538089
Drug: Early treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early treatment response
Study: 17184890
Drug: Topiramate (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiramate (100 mg)
Study: 17184890
Drug: Methamphetamine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methamphetamine (15 mg)
Study: 17184890
Drug: Methamphetamine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methamphetamine (30 mg)
Study: 16084254
Drug: Combination antibiotic
Normalized name: combinations of different antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination antibiotic susceptibility testing (MCBT)
Study: 12898820
Drug: Acute stage
Normalized name: SAGE
DrugBank: Sage (DB10982)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute stage of disease (before treatment)
Study: 12898820
Drug: After clearing
Approvals — FDA: no, EMA: no, PMDA: no
Description: After clearing of skin lesions (after effective treatment)
Study: 7770260
Drug: 2 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g/day of elemental calcium
Study: 7486112
Drug: Nitroprusside treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroprusside treatment
Study: 31116188
Drug: 6-mm-long and
Normalized name: LONG PEPPER
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-mm-long and 4-mm-wide implants
Study: 31116188
Drug: Implants at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implants at least 10-mm long in augmented bone
Study: 28318845
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of positive affect‐oriented communication and positive expectation
Study: 24167605
Drug: Advice to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Advice to take iron supplements
Study: 24167605
Drug: Length of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Length of time that iron supplements had been taken
Study: 17763203
Drug: Indomethacin (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (75 mg bd)
Study: 17763203
Drug: Rofecoxib (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rofecoxib (12.5 mg bd)
Study: 2396471
Drug: 3 x
Normalized name: Xenon (133 xe)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 x S (three doses of suspension-formulated vaccine)
Study: 2396471
Drug: 3 x
Normalized name: Xenon (133 xe)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 x E (three doses of vaccine in enteric-coated capsules)
Study: 2396471
Drug: 2 x
Normalized name: anti-HER2 x HER2 ADC
DrugBank: Zanidatamab zovodotin (DB15472)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 x S (two doses of suspension-formulated vaccine)
Study: 2396471
Drug: 1 x
Normalized name: Black Cohosh 1 X Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 x S (one dose of suspension-formulated vaccine)
Study: 30138543
Drug: Glucocorticoid (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucocorticoid (20 mg prednisolone)
Study: 30138543
Drug: Placebo (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (20 mg Avicel)
Study: 22463922
Drug: SAR236553 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAR236553 50 mg Q2W
Study: 22463922
Drug: SAR236553 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAR236553 100 mg Q2W
Study: 22463922
Drug: SAR236553 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAR236553 150 mg Q2W
Study: 22463922
Drug: SAR236553 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAR236553 200 mg Q4W
Study: 22463922
Drug: SAR236553 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAR236553 300 mg Q4W
Study: 20934557
Drug: 200-mg intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200-mg intravenous bolus of potassium canrenoate followed by a daily 25-mg dose of spironolactone for 6 months
Study: 15725087
Drug: Pre-emptive immunotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-emptive immunotherapy
Study: 6501905
Drug: Purified trivalent
Normalized name: RAYON,PURIFIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Purified trivalent sub‐unit influenza vaccine
Study: 6501905
Drug: 14‐valent pneumococcal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14‐valent pneumococcal vaccine
Study: 30281866
Drug: HDM sublingual
Normalized name: ODACTRA 12 SQ-HDM Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: HDM sublingual tablets (300 index of reactivity) once daily for 52 weeks
Study: 30143003
Drug: Clinical medication
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical medication review (CMR) focused on patients' preferences, personal goals, and health-related complaints.
Study: 30143003
Drug: Secondary outcomes
Normalized name: Secondary potassium phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secondary outcomes include healthcare utilisation, number and type of drug changes, number and type of health-related goals, scores on goal attainment scale (GAS), and number and type of drug-related problems (DRPs) and interventions.
Study: 26414074
Drug: Injection speed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Injection speed of 0.3 ml/s (15 seconds)
Study: 26414074
Drug: Injection speed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Injection speed of 0.15 ml/s (30 seconds)
Study: 26414074
Drug: Injection speed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Injection speed of 0.1 ml/s (45 seconds)
Study: 24899160
Drug: 6 mg/d
Normalized name: EMSAM 6 MG/Day 24HR Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg/d lutein (low-dose)
Study: 24899160
Drug: 12 mg/d
Normalized name: EMSAM 12 MG/Day 24HR Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 mg/d lutein (high-dose)
Study: 24899160
Drug: 0 mg/d
Normalized name: Arixtra 10 mg/dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg/d lutein (placebo)
Study: 22992291
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (73 patients) that continued treatment based on recorded PROMs and clinical assessment.
Study: 15452011
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of strategies
Study: 9186385
Drug: DTP-IPV vaccine
Normalized name: poliovirus vaccine inactivated, type 1 (Mahoney)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTP-IPV vaccine alone (n = 43)
Study: 9186385
Drug: DTP-IPV vaccine
Normalized name: poliovirus vaccine inactivated, type 1 (Mahoney)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTP-IPV vaccine with PVRV (n = 41)
Study: 8233146
Drug: Oral laxatives
Normalized name: Pedia-Lax Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral laxatives
Study: 8233146
Drug: Conditional rectal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conditional rectal cathartics
Study: 3887636
Drug: DHE‐Heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHE‐Heparin
Study: 15293865
Drug: AS 195
Normalized name: levodopa 195 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: AS 195 360mg once daily for 6 weeks
Study: 9683395
Drug: L-tryptophan (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-tryptophan (30 mg/kg)
Study: 7832179
Drug: Cocaine use
Normalized name: Cocaine
DrugBank: Cocaine (DB00907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine use during methadone maintenance (35 mg)
Study: 7832179
Drug: Cocaine use
Normalized name: Cocaine
DrugBank: Cocaine (DB00907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine use during buprenorphine maintenance (2 mg)
Study: 7832179
Drug: Cocaine use
Normalized name: Cocaine
DrugBank: Cocaine (DB00907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine use during buprenorphine maintenance (6 mg)
Study: 7832179
Drug: Cocaine use
Normalized name: Cocaine
DrugBank: Cocaine (DB00907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine use during methadone maintenance (120 mg)
Study: 7832179
Drug: Methadone maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone maintenance (35 mg)
Study: 7832179
Drug: Buprenorphine maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine maintenance (2 mg)
Study: 7832179
Drug: Buprenorphine maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine maintenance (6 mg)
Study: 7832179
Drug: Methadone maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone maintenance (120 mg)
Study: 2979249
Drug: Oral rehydration
Normalized name: Oral rehydration salt formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral rehydration solution (ORS) containing bicarbonate
Study: 2979249
Drug: Oral rehydration
Normalized name: Oral rehydration salt formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral rehydration solution (ORS) without bicarbonate (chloride ions instead)
Study: 24962607
Drug: Oxytocin nasal
Normalized name: oxytocin Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxytocin nasal spray (24 International Units, twice-daily for 6 weeks) combined with social cognition training (2 × 1 hour weekly sessions for 6 weeks)
Study: 24962607
Drug: Placebo nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo nasal spray combined with social cognition training (2 × 1 hour weekly sessions for 6 weeks)
Study: 24962607
Drug: Oxytocin nasal
Normalized name: oxytocin Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxytocin nasal spray (24 International Units, twice-daily for 6 weeks)
Study: 21857390
Drug: Iron supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron supplementation (0, 1, or 2 mg iron/kg/d) from 6 weeks to 6 months of age
Study: 21857390
Drug: Iron supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron supplementation (2 mg group)
Study: 18827732
Drug: 700 microg
Normalized name: Dexamethasone 700 microgram prolonged-release ocular implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: 700 microg dexamethasone drug delivery system via a 22-gauge applicator insertion (n = 20)
Study: 18827732
Drug: 700 microg
Normalized name: Dexamethasone 700 microgram prolonged-release ocular implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: 700 microg dexamethasone drug delivery system via a pars plana incisional placement (n = 10)
Study: 11120722
Drug: Oestrogen alone,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oestrogen alone, oral or transdermal
Study: 11120722
Drug: Implant (oestrogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implant (oestrogen and testosterone)
Study: 9124831
Drug: Once-weekly azithromycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-weekly azithromycin (10 mg/kg)
Study: 9124831
Drug: Once-weekly azithromycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-weekly azithromycin (5 mg/kg)
Study: 9124831
Drug: Once-daily amoxicillin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily amoxicillin (20 mg/kg)
Study: 9124831
Drug: Both azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Both azithromycin and amoxicillin groups
Study: 1433775
Drug: 20 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 g/day arginine hydrochloride
Study: 1433775
Drug: Mixed amino
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed amino acid solution (Travasol)
Study: 20610202
Drug: Chlorhexidine gluconate
Normalized name: Chlorhexidine Gluconate
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorhexidine gluconate (4%) scrub followed by alcohol impregnated with iodine (1%) solution
Study: 26048134
Drug: Olaparib 400
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Olaparib 400 mg (8 × 50 mg capsules) after a standard meal
Study: 26048134
Drug: Olaparib 400
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Olaparib 400 mg (8 × 50 mg capsules) after a high‐fat meal
Study: 26048134
Drug: Olaparib 400
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Olaparib 400 mg (8 × 50 mg capsules) in the fed state (standard meal)
Study: 26048134
Drug: Olaparib 400
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Olaparib 400 mg (8 × 50 mg capsules) in the fed state (high‐fat meal)
Study: 23528399
Drug: Balneopeloid therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balneopeloid therapy with irrigation of high mineralized natural water and application of sapropel mud
Study: 21716273
Drug: Verapamil (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (various doses)
Study: 21716273
Drug: Quinidine (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinidine (various doses)
Study: 15596605
Drug: Donepezil 5
Normalized name: donepezil 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil 5 mg/d for 6 weeks, then 10 mg/d
Study: 9729054
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate (topical corticosteroid)
Study: 2500248
Drug: 20-cm2 nitroglycerin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20-cm2 nitroglycerin adhesive transdermal patch applied for a single 24-hour period (q24hr)
Study: 2500248
Drug: 2% nitroglycerin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% nitroglycerin ointment applied over a 50-cm2 area every eight hours (q8hr)
Study: 528095
Drug: Phenobarbital tablets,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenobarbital tablets, USP, 100 mg (7 different brands)
Study: 528095
Drug: Phenobarbital tablets,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenobarbital tablets, USP, 100 mg (Preparations A and E)
Study: 528095
Drug: Phenobarbital tablets,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenobarbital tablets, USP, 100 mg
Study: 23994951
Drug: Metronidazole 750
Normalized name: metronidazole 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole 750 mg ± miconazole
Study: 23994951
Drug: Metronidazole 500
Normalized name: metronidazole 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole 500 mg ± miconazole
Study: 19246922
Drug: Low-dose aspirin
Normalized name: low-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose aspirin for 14 days
Study: 19246922
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no drugs for 14 days)
Study: 17209663
Drug: Serotonergic drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serotonergic drugs (SSRIs, dexfenfluramine, 5‐HT2C receptor agonists)
Study: 17209663
Drug: Sibutramine, dexfenfluramine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sibutramine, dexfenfluramine, fluoxetine, chlorophenylpiperazine (mCPP)
Study: 17209663
Drug: 5‐HT2C receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐HT2C receptor selective agonists (lorcaserin)
Study: 17209663
Drug: 5‐HT6 receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐HT6 receptor antagonists (PRX‐07034, BVT74316)
Study: 1303863
Drug: 4% Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% Sodium Cromoglycate used twice daily
Study: 1303863
Drug: 2% Sodium
Normalized name: Dextrose 5% and 0.2% Sodium Chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% Sodium Cromoglycate used four times daily
Study: 3856458
Drug: Fenfluramine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenfluramine (60 mg po)
Study: 25114584
Drug: Pregabalin (150-600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin (150-600 mg/day)
Study: 20029243
Drug: Zaltoprofen 160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zaltoprofen 160 mg
Study: 21430410
Drug: Loxoprofen 60
Normalized name: loxoprofen 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loxoprofen 60 mg
Study: 11317660
Drug: Inhaled insulin
Normalized name: insulin, regular, human Inhalation Powder [Afrezza]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled insulin (AERx iDMS) at dosages of 0.3, 0.6, 1.2, and 1.8 U/kg body weight
Study: 11317660
Drug: Subcutaneous insulin
Normalized name: subcutaneous insulin pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous insulin (0.12 U/kg body weight)
Study: 19317821
Drug: Inhaled insulin
Normalized name: insulin, regular, human Inhalation Powder [Afrezza]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled insulin (AERx iDMS)
Study: 19207292
Drug: Orlistat 120
Normalized name: orlistat 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orlistat 120 mg tid
Study: 8236144
Drug: Diltiazem (120,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (120, 240, or 360 mg/day)
Study: 7564036
Drug: Aspirin (81
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (81 mg/day)
Study: 8236144
Drug: Aspirin plus
Normalized name: Aspirin Plus Antacid Extra Strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin plus Diltiazem (81 mg/day + diltiazem)
Study: 28793958
Drug: Amisulpride (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amisulpride (200 mg)
Study: 28793958
Drug: Conventional formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional formulation of amisulpride
Study: 20728093
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose intensity groups
Study: 18922570
Drug: Rofecoxib (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rofecoxib (25 mg)
Study: 11391165
Drug: 800-mg amprenavir
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800-mg amprenavir (APV) combined with 800-mg indinavir (IDV)
Study: 11391165
Drug: 800-mg amprenavir
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800-mg amprenavir (APV) combined with 750-mg nelfinavir (NFV)
Study: 11391165
Drug: 800-mg amprenavir
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800-mg amprenavir (APV) combined with 800-mg saquinavir-Soft Gel Capsule (SGV-SGC)
Study: 11391165
Drug: APV given
Normalized name: FOS-APV
DrugBank: Fosamprenavir (DB01319)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: APV given alone for 3 weeks and then with 150-mg lamivudine (3TC) and 300-mg zidovudine (ZDV)
Study: 10087435
Drug: SK+heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: SK+heparin
Study: 10087435
Drug: rt-PA+heparin
Normalized name: rt-PA
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: rt-PA+heparin